XML 43 R25.htm IDEA: XBRL DOCUMENT v3.25.2
Collaboration and License Agreements (Tables)
 9 Months Ended
Jun. 30, 2025
Collaboration And License Agreements [Abstract]  
Schedule of Revenue
The following table provides a summary of revenue recognized:
Three Months Ended June 30,Nine Months Ended June 30,
2025202420252024
(in thousands)
GSK$143 $— $2,646 $2,685 
Takeda— — — 866 
Sarepta27,624 — 570,330 — 
Total$27,767 $— $572,976 $3,551 
Schedule of Receivables and Contract Liabilities
The following table summarizes the balance of receivables and contract liabilities related to the Company’s collaboration and license agreements:
June 30, 2025September 30, 2024
(in thousands)
Receivables included in accounts receivable$9,699 $— 
Contract liabilities included in deferred revenue$22,979 $— 
Schedule of Fixed and Estimated Variable Consideration The fixed and estimated variable consideration of $904.9 million was allocated in accordance to the following table:
June 30, 2025
(in thousands)
Upfront payment
$500,000 
Annual fees
250,000 
Equity premium
83,612 
Fixed consideration
$833,612 
Estimated variable consideration
71,243 
Total transaction price
$904,855